Sunlight Exposure
Conditions
Brief summary
A three-period parallel (baseline, treatment, and post-treatment) design clinical research was conducted. All participants visited a clinical trial center of Korea University Anam Hospital for baseline measurement of clinical variables including ABPM and hematologic biomarkers (ACTH, aldosterone, norepinephrine, cortisol, and 25-hydroxyvitamin D3). After the baseline assessment, participants visited 'Cholipo beach' (Taean, Republic of Korea) for 3 nights and 4 days for the intervention (sunlight exposure program). After a week of wash-out period, post-treatment measurement was processed at Korea University Anam Hospital. Participants were prohibited from vigorous physical activity, alcohol drinking, and smoking during the study period. A normal-sodium diet (2800 mg/day)\[14\], caffeine and smoking restriction was suggested during the whole study period. To control the effect of circadian rhythm on endocrine blood tests and ABPM, we fixed sampling and monitoring start time at 10:00 am. All participants received the same measurements as they did in the baseline measurement during treatment and post-treatment periods.
Interventions
OTHERSunlight exposure
The weather was sunny and found suitable for outside activity and sunlight exposure program, with a mean temperature of 27.0-28.5 °C, the humidity of 64-80%, and global solar exposure of 1.28 to 2.99 MJ/m2 during treatment.\[15\] Participants were asked to lie on the beach for 45 minutes per day between 2 to 3 pm to avoid extreme skin irritation and sunburn from direct sunlight exposure.
Sponsors
Korea University Anam Hospital
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
PREVENTION
Masking
NONE
Intervention model description
Single group parallel study
Eligibility
Sex/Gender
ALL
Age
20 Years to 45 Years
Healthy volunteers
No
Inclusion criteria
* prehypertensive patients * vitamin D insufficiency * age 20-45
Exclusion criteria
* medical comorbidity other than prehypertension * participant using medication * Subjects with a history of cardiovascular, renal, hepatic, gastrointestinal, hematologic, psychological, or gastrointestinal abnormalities, taking any kind of medications
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Blood pressure | 24 hours | 24 hour ambulatory blood pressure monitoring |
| pulse rate | 24 hours | — |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Age | 3 weeks | Age in years |
| 25-hydroxyvitamin D3 | 3 weeks | ng/mL |
| Weight | 3 weeks | Weight in kilograms |
| Norepinephrine | 3 weeks | pg/mL |
| ACTH | 3 weeks | pg/mL |
| Aldosterone | 3 weeks | ng/mL |
| Height | 3 weeks | Height in meters |
Countries
South Korea
Outcome results
None listed